RandyW Posted January 17, 2009 Share Posted January 17, 2009 Antisoma Commences End-Stage Study Of ASA404 As Second-Line Treatment For Lung Cancer - Update 1/13/2009 3:20 AM ET RELATED NEWS Antisoma enters phase III trial in testing ASA404 as second-line treatment for NSCLC - Quick Facts Antisoma's Oral Fludarabine For Blood Cancer Gets FDA Nod - Update Antisoma receives FDA approval for oral fludarabine - Quick Facts Antisoma Says Mid-Stage Trial For Tumour Agent Shows Positive Results - Update Antisoma reveals positive results from Phase II trial of ASA404 in non-small cell lung cancer - Quick Facts TOP MARKET NEWS Bottom of Economic Cycle Nowhere in Sight Stocks Close Sharply Higher After Seeing Considerable Volatility - U.S. Commentary Variety Of New Releases Should Trigger Strong Overall Box Office Weekend Stocks Turning In A Lackluster Performance In Afternoon Trading - U.S. Commentary Obama's Economic Recovery Plan To Focus On Green Jobs (RTTNews) - Tuesday, biopharmaceutical company Antisoma Plc (ASM.L: News , ATSMY) said that it has commenced a Phase 3 trial evaluating ASA404 as a second-line treatment for non-small cell lung cancer, or NSCLC. ASA404 is a small-molecule Tumour-Vascular Disrupting Agent, which selectively targets the blood vessels that nourish tumours. It was in-licensed by Antisoma from Cancer Research Ventures Limited in August 2001, and the worldwide rights to the drug were licensed to Novartis AG in April 2007. According to the company, the single pivotal study is designed to support applications to market the drug-candidate for lung cancer patients who had a prior round of treatment. The trial is a randomized, placebo-controlled, multi-country study on approximately 900 lung cancer patients under treatment. Antisoma is looking for overall survival as the primary endpoint and expects to conduct a single interim look during 2010. The company anticipates completing the study in 2011. Meanwhile, the company is currently conducting a separate end-stage trial to evaluate the drug candidate in NSCLC patients receiving their first treatment. Earlier, Antisoma said ASA404 showed 5 months improved survival when given along with first line carboplatin and paclitaxel chemotherapy in a randomized mid-stage trial. Antisoma noted that Novartis has decided to explore the potential drug-candidate in previously treated as well as newly diagnosed lung cancer patients. Currently, the stock is up 1 pence, trading at 24.50 pence on the London Stock Exchange. by RTT Staff Writer For comments and feedback: contact email@example.com Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.